Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Thematic (Sector/Industry)

United states Health care / Thematic (Sector/Industry)

<ul><li>With MDMA-Assisted Therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) highly anticipated to become the first Schedule 1 psychedelic-based therapy to be federally legalized in the US by 2Q24, once approved, affordability becomes the key condition for mainstreaming the use of the therapy.</li><li>Progress toward a more robust payor coverage for and broader-based accessibility to psychedelic-assisted therapies (PATs) has taken a major step forward with the recent approval by the American Medical Association (AMA) for the assignment of the first-of-its kind Current Procedural Terminology (CPT) code, an insurance billing code for long-form PAT.</li><li>PAT will be assigned a Category 3 CPT code, effective from the start of 2024, for which payor reimbursement is discretionary.</li></ul>

With MDMA-Assisted Therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) highly anticipated to become the first Schedule 1 psychedelic-based therapy to be federally legalized in the US by 2Q24, once approved, affordability becomes the key condition for mainstreaming the use of the therapy.Progress toward a more robust payor coverage for and broader-based accessibility to psychedelic-assisted therapies (PATs) has taken a major step forward with the recent approval by the American Medical Association (AMA) for the assignment of the first-of-its kind Current Procedural Terminology (CPT) code, an insurance billing code for long-form PAT.PAT will be assigned a Category 3 CPT code, effective from the start of 2024, for which payor reimbursement is discretionary.

Shroom Shmooz : Why Getting a CPT Code Is a Big Deal for Psychedelic Therapies